NCT07741071: N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
- State
- Under way
- Phase
- Phase 2
- People
- 270 planned
- Started
- 26 Aug 2026
- Primary completion
- 30 Apr 2030
- Arms
- Nicotinamide Riboside (NR)
- Results
- None posted
- 3 Aug 2026: Trial registered